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In a previous report (1), preliminary observations on the
treatment of six psoriatic patients by means of lipocaic were
presented. Four of these patients showed marked improvement
and two failed to respond. The improvement seemed to coincide
with a lowering of the blood lipid level which had been found to
be elevated in three of the patients. Further observations on
these six patients and an additional seventeen patients form the
basis of this report.
Lipocaic (2) is a hormone contained in a defatted alcoholic
extract of the pancreas which appears to play some role in the
metabolism or transport of fat. When given to depancreatized
dogs which are receiving insulin and are on a normal diet, it
prevents the fatty infiltration of the liver which usually develops
in these animals. However, if the dogs are fed a fat free diet
lipocaic is not required to prevent this change. Its use in
psoriasis was suggested by the well known contention of some
investigators that this disease is the result of a deranged fat
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metabolism, and the fact that lipocaic has been found to reduce
the abnormally high blood lipids found in persons with xanthoma.
In the present study, twenty-three patients were observed
for from two to eighteen months. There were eight women
and fifteen men; their ages ranged from ten to sixty-seven years.
The patients were selected chiefly on their willingness to cooperate.
They presented lesions of all types which had been present for
from seven months to many years. About half of them had a
fairly generalized eruption and in one quarter it was of recent
onset or represented exacerbation of chronic psoriasis. The
remainder had lesions of varying severity on the usual sites of
predilection, namely, the elbows, knees, scalp and sacral region.
Treatment consisted at first only of the administration of
lipocaic capsules. Each contained one-half gram of pancreatic
extract which was equivalent to twenty-five grams of raw pan-
creas. The dosage per day ranged from eight to twenty-eight
capsules. Later, in some cases which responded slowly or not
at all to lipocaic, five per cent crude coal tar ointment, or 0.10—0.25
per cent anthraline ointment were used on all lesions except those
on the scalp where five or ten per cent ammoniated mercury was
applied. The patients returned at two to four week intervals
and blood was drawn for the determination of the total fasting
blood serum lipids by gravimetric analysis.
The present data do not bear out some of the tentative con-
clusions in the first report. Lipocaic does not, as was first
thought, tend to lower the blood lipid level in psoriatic patients
nor is improvement of the psoriasis necessarily accompanied by
any change in the level of the blood lipids. Thus, if lipocaic
does influence psoriasis through a change in the blood lipids, it
probably is a qualitative and not a quantitative change.
To determine whether or not a treatment of psoriasis which
depends chiefly on crude coal tar causes any change in the blood
lipid level, a patient, who had previously received lipocaic without
effect, was hospitalized and treated with 5 per cent crude coal
tar ointment, ultraviolet light, autohemic injections and mild
sedation. The psoriasis cleared completely in four weeks but
there was no significant change in the level of the blood lipids.
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That crude coal tar, which is an effective drug in the treatment
of psoriasis may also produce its effect through qualitative altera-
tion in the blood fats when applied locally, is suggested by the
following work of Hansen (3). It was found that the blood fats in
children with infantile eczema had an abnormally low iodine
number, i.e., contained less than the normal percentage of un-
saturated fatty acids. When crude coal tar ointment was ap-
plied locally to the eruption, there was a rise in the percentage of
unsaturated fatty acids in the blood as indicated by an increase
in the iodine number. This change was concurrent with clinical
improvement of the eczema.
RESULTS OF TREATMENT
However, that there does seem to be some correlation between
the blood lipid level and the response to lipocaic therapy is
brought out in table 1.
TABLE 1
TREATMENT WITH LIPOCAIC ALONE,
22 PATIENTS
TREATMENT WITH LIPOC4IC PLUS
LOCAL APPLICATION, 12 PATIENTS
Cleared Improved chge Cleared Improved ohge
No. of cases
Per cent
Average blood lipid..
7 11 4
31.8 50.0 18.2
656 796 833
3 6 3
25 50 25
721 783 896
The table shows the results for the period when the patients
were receiving lipocaic alone and also for the combined treatment
period. The average blood lipid of the patients whose eruption
cleared with lipocaic (656 mg. per cent) was much lower than
that of any other group. Those who were not benefited by
lipocaic even when combined with local applications showed
the highest average level (896 mg. per cent). Patients who
improved or were entirely refractory to lipocaic treatment and
those that cleared or improved with combined treatment showed
intermediate values (796, 833, 721 and 783 mg. per cent re-
spectively). In all, 31 per cent were cleared, 51 per cent im-
proved and 18 per cent showed no change with lipocaic alone.
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If 750 mg. per cent is considered to be the upper limit of the
normal range for fasting blood lipids by the method used, 13 or
56 per cent of the patients had an abnormally high level. These
13 patients include only one of the group which cleared with
lipocaic alone (763 mg. per cent). Another rather striking
correlation was noted between the blood lipid level and the age
of the patients. They were divided arbitrarily into two groups,
those thirty years of age and under and those over thirty. The
younger group (11 patients) had an average blood lipid of 678
mg. per cent and included five of the seven patients whose erup-
tions cleared with lipocaic alone. The older group (12 patients)
had an average of 833 mg. per cent and included all of the patients
whose eruptions showed no response to either treatment.
Besides this apparent relationship between the blood lipid level
and the effect of lipocaic in improving psoriasis, there are several
other observations which indicate that this substance has a
specific action on the disease. In practically all the cases, there
was a change in the character of the scales during the first two to
four weeks of treatment. They became finer and drier and in
many cases decreased in amount. At the same time the lesions
often became paler and less elevated. Secondly, the improve-
ment usually was effected during the winter months when psoriasis
tends to become worse. Thirdly, the three patients who were
cleared by using both lipocaic and local applications found that
neither alone would keep them free from lesions.
Special mention in some detail should be made of the further
course of the six patients originally reported. They have now
been under observation from 12 to 18 months, four of them
through two winters. In the four patients whose skin cleared
with lipocaic alone, the capsules were stopped in April or May
1939 and they were considered "cured" even though some still
had very small lesions on the elbows or knees. All four have
had recurrences. One occurred in July and the lesions disap-
peared in two weeks when six capsules a day were taken. The
same patient had a more severe recurrence in January 1940
but with larger doses of lipocaic the lesions went through the
same changes mentioned above and her skin cleared gradually.
Another patient returned with a severe recurrence in September
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1939. She was started on lipocaic and in eight weeks showed
the usual change with central clearing. She was unable to
continue treatment at that time and when last heard from she
bad bad an extensive eruption all during the winter and spring.
The two remaining patients who were benefited returned in
November 1939 and March 1940 with a few lesions. These
improved after administration of lipocaic, although the patients
continued to have a few small pale lesions which would come and
go from week to week. Thus lipocaic seems to be equally effec-
tive when used for treatment of recurrences in contrast to many
anti-psoriatic remedies which are less effective in the treatment of
recurrences than when used for the first time.
The two patients who were not helped by lipocaic alone both
returned in the fall because the psoriasis had gotten worse. We
again gave lipocaic but in larger doses. One whose average
blood lipid level was 690 mg. per cent was entirely clear in Feb-
ruary. The other with an average blood lipid of 1003 mg. per
cent has not responded to any ambulatory treatment including
ultraviolet light, crude coal tar ointment and x-ray.
Another patient deserving special consideration was a 10
year old girl who had been under observation for five years,
most of that time having been spent in a hospital. She had a
dermatitis, most severe on the face, scalp, arms and legs but at
times generalized, which was characterized by erythema, scal-
ing and crusting. It had been diagnosed by various dermatol-
ogists as seborrheic dermatitis, seborrheic psoriasis, pustular
psoriasis and "psoriasoid." Treatment of all types had been
tried but the disease had never been cured. The average blood
lipid level was 821 mg. per cent. She was started on lipociac
and immediate improvement was noted in the skin. The drug
has been stopped several times and each time an exacerbation
occurred. No change was produced in the blood lipid level.
Little is known about the effects of large doses of lipociac since
its exact role in the metabolic processes is not known. In general
there was no effect on, the patients' health or weight. Several
stated that they felt better when taking the drug. Over half
of the patients noted a laxative effect especially with the higher
doses. This was probably due to the relatively large amount
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of inorganic salts, principally NaSO4, which remains from the
extracting process. Some patients experienced mild abdominal
cramps after taking the capsules, probably for the same reason.
There was no correlation between the laxative effect and the skin
changes. One patient, while taking 25 capsules a day, devel-
oped dizziness, weakness, nausea, vomiting and diarrhea. Dis-
continuance of the drug relieved the symptoms entirely. One
patient developed amyotrophic lateral sclerosis while taking
lipocaic, which seems to have been an entirely coincidental
occurrence.
COMMENT
The many points on which this study is open to criticism are
fully realized. For a disease which is subject to as definite spon-
taneous and seasonal variations as psoriasis, this is a relatively
small series of patients observed over a short period of time.
The lipocaic used was by no means a pure product, could not be
accurately standardized, and may have varied considerably in
potency. No control series using sodium sulfate alone or some
entirely inert substance was observed. Nevertheless, despite
these shortcomings, it is felt, for the reasons stated above, that
these data do support the contention that psoriasis is in some
way related to lipoid metabolism, possibly through both a
quantitative and qualitative alteration in the blood lipids. Also,
some factor in the material given these patients, probably
lipocaic, has a definite beneficial effect on psoriatic lesions which
is more evident in patients with a low fasting blood lipid level.
It is hoped that through further study of the lipoid chemistry
of these patients by determinations of lipoid fractions, choles-
terol tolerance curves, iodine number, the effect of fat free diets,
the effect of Vitamin D on the blood lipids, etc., more light can
be shed both on the mode of action of lipocaic and the underlying
cause of psoriasis.
SUMMARY
In twenty-three psoriatic patients observed for from two to
eighteen months who were treated by the oral administration of
lipocaic alone, clearing of the lesions occurred in 31 per cent,
improvement in 50 per cent and no change in 19 per cent.
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Lipocaic did not cause a reduction of the blood lipid level in
patients with psoriasis as had first been thought but patients
with a low blood lipid cleared more readily with lipocaic or
lipocaic plus local treatment than those with high blood lipid
levels.
Younger patients had a lower average blood lipid than those
in the older age group.
Lipocaic causes a drier and finer type of scaling from psoriatic
lesions.
The data presented supports the belief that psoriasis is in
some way a manifestation of a disturbed lipoid metabolism.
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DISCUSSION
DR. ERICH URBACU, PHILADELPHIA: It is very interesting that lipocaic has
proven of much value in the treatment of psoriasis.
At the International Dermatological Congress in Budapest (1935) I disagreed,
as I still do, that psoriasis is basically a disturbance of lipoid metabolism. Al-
though it is true that a diet low in fats is one of the greatest helps at present in
certain cases, the improvement can be mostly attributed to the resultant loss of
weight as demonstrated by equally good results with other weight-reducing diets.
Schamberg of Philadelphia showed this with a low protein diet, and during the
World War we had the opportunity of seeing the startling effect of severe restric-
tions of diet on the incidence of psoriasis in Austria. Some years later, when
food was plentiful, there was a marked increase in psoriasis.
There is no question but that there is some connection between diabetes and
psoriasis and that carbohydrates and lipoids have something to do with psoriasis.
I am inclined to believe that this connection is rather a complex one. It seems to
me that psoriasis and metabolic disturbances do not stand in relationship of
cause and effect but rather are components of a common mechanism, at present
unknown.
66 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
DR. JOHN F. MADDEN, St. Paul: This has been a most interesting and unusual
report. Although improvements and cures are very high—almost eighty per
cent—a number of other things used for psoriasis have done equally well. The
most interesting fact to me was that lipocaic not only controlled the disease when
it was first used, but that it also controlled recurrence.
In a large series of cases over a number of years I have found many remedies,
which would almost entirely control psoriasis the first time the remedy was used.
When the patient had a recurrence the previously effective remedy often had no
effect whatsoever.
Another point which, I think, Dr. Becker should bring out, is the fact that
lipocaic is not generally available, and the reasons why it is not available.
DR. PAUL Gaoss, New York City: As I pointed out in my paper, Gavin and
McHenry have demonstrated in rats, that the lipotropic function of lipocaic is
also present in rice polish concentrate and Brewer's yeast. This will explain the
good results which I obtained recently in two cases of psoriatic erythroderma by
injections of liver extract. One was a case of generalized psoriatic erythroderma
in an old lady, of two years duration. The erythroderma cleared up but the
patches of psoriasis remained. After continuous therapy with oral administra-
tion of liver extract, even the more resistant lesions disappeared, recently. The
other case, was one seen at the Presbyterian Hospital only a short while ago. It
was a case of gold dermatitis in a patient suffering from psoriasis and arthropathy.
The generalized gold dermatitis was transformed into a psoriatic erythroderma,
but under intensive liver therapy, not only the erythroderma cleared up com-
pletely, but even old psoriatic lesions disappeared temporarily. It is interesting
to note that liver therapy for psoriasis was recommended more than ten years ago.
DR. LAWRENCE C. GOLDBERG, Cincinnati: Would we obtain the same results
as are obtained with Lipocaic if we gave the patient fresh whole pancreas? This
might be advisable inasmuch as the material is unavailable at this time.
DR. HAMILTON MONTGOMERY, Rochester, Minnesota: I have seen several cases
where one or two members in a family had psoriasis and yet had normal or low
blood plasma lipoids and a third member had marked increase in all the blood
plasma lipoids. The majority of cases of psoriasis show no appreciable change
either relative or quantitative in the various blood plasma lipoids. Practically
all patients with psoriasis, almost without exception, respond satisfactorily to
treatment as outlined by Dr. Goeckerman using crude coal tar and ultraviolet
light. This method of treatment works equally well the second and third time
as it does the first time. The response to crude coal tar and ultraviolet light
treatment does not vary according to the blood plasma lipoids of the individual
case. Dr. Brunsting has had distinct success in quite a few cases of psoriasis
treated with large doses of vitamin D. We have not had any experience in the
use of lipocaic inasmuch as it has been difficult to obtain in sufficient amounts.
DR. M. H. GOODMAN, Baltimore: Prom the work of Urbach and Madsen, dis-
turbance of fat metabolism in psoriasis cannot be spelled in terms of quantitative
measurements of lipidoids in the blood. It would be interesting to know what
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proportion of the individuals treated with lipocaic were obese, and what propor-
tion were thin.
In the work of both Urbach and Madsen, it is not so much quantitative differ-
ence in lipid content of the blood, but rather the shift in the metabolism of fat
which seems to affect or influence favorably the individual with psoriasis. It
would seem that if lipocaic, in some manner, produces an alteration in fat metab-
olism the obese psoriatic would profit from it in the same way as he might from
a low fat diet.
DR. THEODORE COENBLEHT, Chicago: From my investigations, it appears that
the glycogen content of the skin in psoriasis is raised above and the glucose level
depressed below that found in the normal skin. Without further information it
cannot be said that these findings are related to the cause of psoriasis, result
from it, or merely incidental. The same may be said about the altered blood
lipoid pattern commonly found in psoriasis. Carbohydrate and fat metabolism
can be related and alterations in both are well known in disease, as in diabetes.
Similarly, some interrelationship may be present in psoriasis. My feeling about
the purely fat metabolic theory of psoriasis, however, is that the changes are not
sufficiently consistent to be of etiologic significance. For this reason, while I
hope lipocaic is what all of us are seeking for the use against the scourge of pso-
riasis, my belief is that as an attack on the deranged fat metabolism, it will prove
to be only a partial aid in some cases.
DR. S. WzLLIi BECKER, Chicago: I appreciate this discussion. You realize
the difficulties under which we are laboring.
We know that lipocaic does regulate lipids because depancreatized dogs treated
with insulin will always die with fatty livers if they are kept on a normal diet
unless they are given whole pancreas or a similar material. Treatment by li-
pocaic is not presented as the best therapy. Dr. Goeckerman's combination
has, in our experience, given about one hundred per cent results, but it practically
means hospitalization. In answer to Doctor Madden, lipocaic is not available
because it is made for experimental use, and when the manufacturers make li-
pocaic it is necessary to stop the production of insulin and use the apparatus for
making lipocaic. They are now doing experimental work on the residue to see
whether lipocaic can be obtained from it.
It is difficult to be sure that lipocaic is present in a pancreatic extract. The
only sure way to assay lipocaic in a given material is to give it to depancreatized
dogs. The dogs should also be given insulin, and if they do not die, then we
may be certain that lipocaic is present in the material. This is a long drawn out
and unsatisfactory procedure, but it is the best we have at present. We have
had no experience in the feeding of fresh whole pancreas.
In reply to Dr. Goodman, most patients have been rather thin. We have
had no opportunity to observe the clearing of psoriatic eruptions following the
use of Fowler's solution. I have never seen as spectacular changes in a psoriatic
eruption without therapy. Lesions heal in the center and eventually the entire
eruption disappears in some patients.
We feel that if lipocaic is only an adjunct to other treatments for psoriasis,
it is a very convenient therapeutic measure, is taken simply by mouth, and we
hope that when it is made available in the not too distant future it may be of help
in the management of this extremely stubborn disease.
